http://cmlsupport.gn.apc.org/daily1.0 http://cmlsupport.gn.apc.org/section/resources2019-03-18T15:45Znever http://cmlsupport.gn.apc.org/section/about-cml2021-07-22T15:10Znever http://cmlsupport.gn.apc.org/section/10-facts-about-cml2021-07-23T16:11Znever http://cmlsupport.gn.apc.org/article/cancer-drugs-fund2015-10-07T08:58Znever http://cmlsupport.gn.apc.org/article/effect-proton-pump-inhibitor-pharmacokinetics-imatinib2015-10-13T12:08Znever http://cmlsupport.gn.apc.org/article/musculoskeletal-pain-tki-withdrawal-syndrome2015-11-05T11:58Znever http://cmlsupport.gn.apc.org/event/online-broadcast-event-cml-patients-journey2015-11-06T16:16Znever http://cmlsupport.gn.apc.org/article/re-emergence-interferon-%CE%B1-treatment-chronic-myeloid-leukemia2015-11-07T13:54Znever http://cmlsupport.gn.apc.org/article/discontinuation-dasatinib-patients-chronic-myeloid-leukaemia-who-have-maintained-deep2015-11-11T11:40Znever http://cmlsupport.gn.apc.org/article/laboratory-recommendations-scoring-deep-molecular-responses-following-treatment-chronic2016-04-30T11:42Znever http://cmlsupport.gn.apc.org/clinical-trials/bfore2015-11-15T19:23Znever http://cmlsupport.gn.apc.org/clinical-trials/dasfree2015-11-15T19:59Znever http://cmlsupport.gn.apc.org/clinical-trials/panobinostat-lbh589-and-imatinib-mesylate-treating-patients-previously-treated2015-11-15T20:17Znever http://cmlsupport.gn.apc.org/clinical-trials/epic2015-11-15T20:25Znever http://cmlsupport.gn.apc.org/clinical-trials/nilotinib-and-lde225-treatment-chronic-or-accelerated-phase-myeloid-leukemia2015-11-15T20:44Znever http://cmlsupport.gn.apc.org/clinical-trials/choices2015-11-15T20:34Znever http://cmlsupport.gn.apc.org/clinical-trials/spirit-22015-11-15T20:40Znever http://cmlsupport.gn.apc.org/article/ash-abstract-137-osteoarticular-pain-after-discontinuation-tyrosine-kinase-inhibitors-tki2015-12-09T11:54Znever http://cmlsupport.gn.apc.org/article/prof-steve-obriens-summary-ash-20152015-12-17T14:01Znever http://cmlsupport.gn.apc.org/article/international-cml-foundation-november-2015-newsletter2015-12-21T18:02Znever http://cmlsupport.gn.apc.org/article/government-responds-cancer-drugs-fund-petition-blood-cancer2015-12-23T13:05Znever http://cmlsupport.gn.apc.org/article/prognosis-long-term-survival-considering-disease-specific-death-patients-chronic-myeloid2016-01-06T20:00Znever http://cmlsupport.gn.apc.org/article/5-years-nilotinib-offers-benefit-over-imatinib-cml2016-02-11T17:46Znever http://cmlsupport.gn.apc.org/article/cell-marker-found-leukemia-initiating-capacity-chronic-myelogenous-leukemia2016-02-18T14:45Znever http://cmlsupport.gn.apc.org/article/mtss1-protein-may-act-tumor-suppressor-downregulated-cml2016-02-20T17:30Znever http://cmlsupport.gn.apc.org/article/tkis-cml-linked-vascular-events2016-02-20T17:40Znever http://cmlsupport.gn.apc.org/article/tgf-alpha-il-6-levels-predict-responses-and-outcomes-cml2016-03-24T17:20Znever http://cmlsupport.gn.apc.org/article/dasatinib-commonly-induces-lymphocytosis-cml-patients2016-03-31T14:35Znever http://cmlsupport.gn.apc.org/article/mtss1-critical-epigenetically-regulated-tumor-suppressor-cml2016-04-06T14:39Znever http://cmlsupport.gn.apc.org/article/european-leukemianet-recommendations-management-cml2016-04-15T11:37Znever http://cmlsupport.gn.apc.org/article/long-term-benefits-and-risks-frontline-nilotinib-vs-imatinib-chronic-myeloid-leukemia-02016-05-05T14:12Znever http://cmlsupport.gn.apc.org/article/pegifn-improves-responses-dasatinib-newly-diagnosed-cml-patients2016-05-21T13:12Znever http://cmlsupport.gn.apc.org/event/cml-patient-support-group-meeting-glasgow2016-05-31T19:57Znever http://cmlsupport.gn.apc.org/event/uk-cml-patient-conference-20162016-06-03T15:19Znever http://cmlsupport.gn.apc.org/videos/what-cml2016-06-04T13:25Znever http://cmlsupport.gn.apc.org/clinical-trials/ascembl-02021-07-27T10:53Znever http://cmlsupport.gn.apc.org/videos/resistant-cml2016-06-23T15:59Znever http://cmlsupport.gn.apc.org/videos/how-should-cp-phase-cml-management-be-influenced-rt-pcr-3-months2016-06-23T16:20Znever http://cmlsupport.gn.apc.org/article/dasatinib-imatinib-resistant-or-intolerant-chronic-phase-chronic-myeloid-leukaemia-patients2016-07-18T19:33Znever http://cmlsupport.gn.apc.org/videos/what-if-what-now2016-08-02T18:07Znever http://cmlsupport.gn.apc.org/videos/what-if-what-now-living-cml2016-08-02T18:09Znever http://cmlsupport.gn.apc.org/article/concept-treatment-free-remission-cml2016-08-04T15:35Znever http://cmlsupport.gn.apc.org/article/european-leukemianet-recommendations-management-and-avoidance-adverse-events-treatment-cml2016-08-04T15:56Znever http://cmlsupport.gn.apc.org/videos/detecting-cml-digital-pcr2016-08-26T18:12Znever http://cmlsupport.gn.apc.org/videos/measuring-molecular-responses-tyrosine-kinase-inhibitors-chronic-myeloid-leukaemia-ecancer2016-08-26T18:16Znever http://cmlsupport.gn.apc.org/article/impact-dose-intensity-ponatinib-selected-adverse-events-multivariate-analyses-pooled2016-09-02T13:54Znever http://cmlsupport.gn.apc.org/article/combined-targeting-bcl-2-and-bcr-abl-tyrosine-kinase-eradicates-chronic-myeloid-leukemia2016-09-07T20:52Znever http://cmlsupport.gn.apc.org/article/abl001-treating-cml-timothy-p-hughes-md2016-09-10T14:46Znever http://cmlsupport.gn.apc.org/article/webcast-link-cml-patient-day-2016-saturday-24th-september2016-09-17T12:38Znever http://cmlsupport.gn.apc.org/article/closer-cure-researchers-centres-us-and-scotland-have-discovered-ways-target-leukaemic-stem2016-09-17T10:36Znever http://cmlsupport.gn.apc.org/section/cml-treatment-guidelines-tki2021-07-01T07:59Znever http://cmlsupport.gn.apc.org/article/long-term-follow-french-stop-imatinib-stim1-study-patients-cml2016-11-15T11:48Znever http://cmlsupport.gn.apc.org/article/outcomes-euro-ski-trial-and-british-destiny-study-reported-ash-meeting-san-diego-show2016-12-08T14:48Znever http://cmlsupport.gn.apc.org/videos/mutation-screening2016-12-08T17:08Znever http://cmlsupport.gn.apc.org/videos/molecular-monitoring-cml-getting-safe-place2016-12-08T17:09Znever http://cmlsupport.gn.apc.org/article/increased-proportion-mature-nk-cells-associated-successful-imatinib-discontinuation-cml2016-12-13T17:29Znever http://cmlsupport.gn.apc.org/article/adding-pioglitazone-could-improve-molecular-response-cml-patients2017-01-08T13:43Znever http://cmlsupport.gn.apc.org/article/destiny-cml-patients-stable-molecular-responses-safely-halved-tki-dose2017-01-08T13:51Znever http://cmlsupport.gn.apc.org/videos/brian-druker-meeting-new-challenges-cml-therapy2017-02-11T07:14Znever http://cmlsupport.gn.apc.org/article/strategies-stopping-tkis-growing-clearer2017-04-02T14:34Znever http://cmlsupport.gn.apc.org/article/maternal-fetal-and-neonatal-imatinib-levels-treatment-chronic-myeloid-leukemia-pregnancy2017-05-13T14:54Znever http://cmlsupport.gn.apc.org/article/natural-killer-cell-counts-are-associated-molecular-relapse-free-survival-after-imatinib2017-06-27T13:09Znever http://cmlsupport.gn.apc.org/article/treatment-free-remission-following-frontline-nilotinib-patients-cml-chronic-phase-results2017-07-08T16:15Znever http://cmlsupport.gn.apc.org/article/striving-vanquish-leukaemia-combination-two-compounds-shows-promise-lab2017-07-20T16:39Znever http://cmlsupport.gn.apc.org/article/frequency-rare-bcr-abl1-fusion-transcripts-chronic-myeloid-leukemia-patients2017-07-29T11:26Znever http://cmlsupport.gn.apc.org/article/stopping-drug-therapy-cml-euro-ski-results2017-07-29T16:26Znever http://cmlsupport.gn.apc.org/article/memoriam-tessa-holyoake2017-09-09T15:54Znever http://cmlsupport.gn.apc.org/videos/treatment-outcomes-bosutinib-real-world-data2017-09-11T15:51Znever http://cmlsupport.gn.apc.org/videos/factors-affecting-clinical-decision-making-refractory-and-relapsed-cp-cml-patients2017-09-11T15:52Znever http://cmlsupport.gn.apc.org/videos/how-treat-cml-20172017-09-11T15:53Znever http://cmlsupport.gn.apc.org/article/targeted-antibiotic-use-may-help-cure-chronic-myeloid-leukaemia2017-09-28T19:11Znever http://cmlsupport.gn.apc.org/article/car-t-cells-engineering-patients-immune-cells-treat-their-cancer2017-11-02T16:20Znever http://cmlsupport.gn.apc.org/publications2021-07-27T11:05Znever http://cmlsupport.gn.apc.org/section/generic-imatinib-leaflet2017-12-06T14:53Znever http://cmlsupport.gn.apc.org/section/pcr-booklet2022-03-18T10:34Znever http://cmlsupport.gn.apc.org/article/once-day-nilotinib-real-life-observational-study2018-04-23T16:44Znever http://cmlsupport.gn.apc.org/videos/icmlf-forum-2017-perspectives-molecular-monitoring-cml-global-perspective2018-01-31T13:17Znever http://cmlsupport.gn.apc.org/videos/icmlf-forum-2017-qa-session-1-perspectives-molecular-monitoring-cml2018-01-31T13:16Znever http://cmlsupport.gn.apc.org/videos/icmlf-forum-2017-perspectives-treatment-free-remission-global-perspective2018-01-31T13:18Znever http://cmlsupport.gn.apc.org/videos/icmlf-forum-2017-perspectives-treatment-free-remission-perspectives-brazil2018-01-31T13:19Znever http://cmlsupport.gn.apc.org/videos/icmlf-forum-2017-qa-session-2-perspectives-treatment-free-remission2018-01-31T13:20Znever http://cmlsupport.gn.apc.org/article/pancreatic-enzyme-elevation-patients-treated-nilotinib2018-02-20T12:07Znever http://cmlsupport.gn.apc.org/article/considerations-successful-treatment-free-remission2018-02-26T16:03Znever http://cmlsupport.gn.apc.org/article/long-term-outcome-nilotinib-400-mg-twice-daily-first-line-treatment2018-03-01T16:04Znever http://cmlsupport.gn.apc.org/article/dasatinib-dose-management-treatment-chronic-myeloid-leukemia2018-02-28T13:11Znever http://cmlsupport.gn.apc.org/article/help-cml-support-registering-amazonsmile2018-03-01T16:33Znever http://cmlsupport.gn.apc.org/article/early-results-lower-dose-dasatinib-50-mg-daily-frontline-therapy2018-05-06T10:00Znever http://cmlsupport.gn.apc.org/article/cml-patients-deep-molecular-responses-tki-have-restored-immune-effectors-and-decreased-pd-12018-07-09T13:21Znever http://cmlsupport.gn.apc.org/article/chronic-myeloid-leukemia-and-pregnancy-patient-and-partner-perspectives2018-07-29T16:12Znever http://cmlsupport.gn.apc.org/uk-cml-patient-conference-20182018-09-25T21:15Znever http://cmlsupport.gn.apc.org/article/pepsi-or-coke-influence-acid-dasatinib-absorption2018-08-21T16:23Znever http://cmlsupport.gn.apc.org/article/bcr-abl1-levels-increase-peripheral-blood-not-granulocytes-after-physical-exercise2018-08-21T16:25Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-day-chronic-myeloid-leukaemia-what-it2018-09-25T19:47Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-day-imatinib-where-are-we-now-what-about-generic-imatinib2018-09-25T19:48Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-day-how-response-treatment-measured-pcr-assay2018-09-25T19:49Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-day-2nd-3rd-generation-tkis-nilotinib-dasatinib-ponatinib-bosutinib-when2018-09-25T19:50Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-day-questions-panel-session-12018-09-25T19:51Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-day-patient-stories-richard-willoughby2018-09-25T19:52Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-day-patient-stories-alastair-cameron2018-09-25T19:53Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-day-side-effects-and-how-manage-them2018-09-25T19:54Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-day-adherence-tki-therapy-still-problem2018-09-25T19:55Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-day-update-clinical-trials-and-what%E2%80%99s-new2018-09-25T19:55Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-day-questions-panel-session-22018-09-25T19:57Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-day-questions-panel-session-32018-09-26T07:41Znever http://cmlsupport.gn.apc.org/videos/2018-uk-patient-daydestiny-clinical-trial-and-stopping-treatment-who-and-when-prof-richard2018-09-25T21:13Znever http://cmlsupport.gn.apc.org/article/%C2%A33m-award-pioneering-scottish-trial-leukaemia-cml2018-09-27T15:10Znever http://cmlsupport.gn.apc.org/article/uclh-study-web-based-video-consultations2018-12-13T13:00Znever http://cmlsupport.gn.apc.org/article/e13a2-bcr-abl1-transcript-associated-higher-rates-molecular-recurrence-after-tfr-attempts2018-12-08T07:25Znever http://cmlsupport.gn.apc.org/article/falsified-iclusig-ponatinib-traded-globally2019-03-05T15:50Znever http://cmlsupport.gn.apc.org/videos/making-tfr-mainstream2019-03-12T10:03Znever http://cmlsupport.gn.apc.org/videos/prognostic-biomarkers-cml2019-03-12T10:06Znever http://cmlsupport.gn.apc.org/videos/immunology-cml-and-immunomodulation2019-03-12T10:05Znever http://cmlsupport.gn.apc.org/videos/we-do-still-transplant-cml-dont-we2019-03-12T17:16Znever http://cmlsupport.gn.apc.org/videos/importance-molecular-monitoring-cml-how-deep-how-often-and-how-should-it-influence-therapy2019-03-12T17:17Znever http://cmlsupport.gn.apc.org/article/skeletal-muscle-toxicity-associated-tkis-cml-patients2019-03-18T15:39Znever http://cmlsupport.gn.apc.org/article/tki-discontinuation-criteria-established-updated-nccn-guidelines2019-03-27T16:30Znever http://cmlsupport.gn.apc.org/article/early-results-lower-dose-dasatinib-50%E2%80%89mg-daily-frontline-therapy2021-08-23T14:52Znever http://cmlsupport.gn.apc.org/article/cml-horizons-conference-report-lisbon-portugal-may-17th-19th-20192019-05-28T11:26Znever http://cmlsupport.gn.apc.org/article/de-escalation-tki-therapy-complete-treatment-discontinuation-patients-cml2019-06-26T18:14Znever http://cmlsupport.gn.apc.org/article/kings-college-london-patient-group-july-24th2019-06-29T20:21Znever http://cmlsupport.gn.apc.org/article/cml-horizons-2019-presentations-and-video-streams-are-available-now2019-07-06T10:53Znever http://cmlsupport.gn.apc.org/article/uk-chronic-myeloid-leukaemia-patient-day-20192019-10-13T15:06Znever http://cmlsupport.gn.apc.org/videos/ngs-cml-new-standard-diagnostic-procedure2019-08-04T07:50Znever http://cmlsupport.gn.apc.org/article/cortes-highlights-second-generation-tkis-frontline-therapy-cml2019-08-09T09:59Znever http://cmlsupport.gn.apc.org/article/cml-concepts-resistance-and-persistence-and-relationship-bcr-abl12019-10-06T21:12Znever http://cmlsupport.gn.apc.org/article/long%E2%80%90term-follow%E2%80%90-lower-dose-dasatinib-50-mg-daily-frontline-therapy-newly-diagnosed-chronic2019-10-06T21:11Znever http://cmlsupport.gn.apc.org/article/combining-asciminib-ponatinib-suppresses-emergence-highly-resistant-bcr-abl1-mutants2019-10-07T10:04Znever http://cmlsupport.gn.apc.org/article/cessation-nilotinib-patients-cml-who-have-kept-deep-molecular-responses-2yrs2019-10-07T10:04Znever http://cmlsupport.gn.apc.org/videos/what-side-effects-do-i-need-know-about-and-how-can-i-manage-them-dr-dragana-milojkovic2019-10-11T14:53Znever http://cmlsupport.gn.apc.org/videos/patient-stories-living-cml2019-10-11T15:13Znever http://cmlsupport.gn.apc.org/videos/your-clinical-nurse-specialist-what-do-they-offer2019-10-11T15:13Znever http://cmlsupport.gn.apc.org/videos/community-monitoring-%E2%80%93-leeds-experience2019-10-11T15:14Znever http://cmlsupport.gn.apc.org/videos/cml-support-patients-and-carers2019-10-11T16:35Znever http://cmlsupport.gn.apc.org/videos/update-clinical-trials-and-new-agents2019-10-11T16:36Znever http://cmlsupport.gn.apc.org/videos/reducing-or-stopping-treatment-who-and-when2019-10-11T16:40Znever http://cmlsupport.gn.apc.org/videos/psychological-aspects-diagnosis-and-treatment-%E2%80%93-coping-strategies-living-well2019-10-11T16:56Znever http://cmlsupport.gn.apc.org/videos/stem-cell-transplantation-%E2%80%93-when-might-be-needed2019-10-11T16:57Znever http://cmlsupport.gn.apc.org/videos/questions-answers-panel-02019-10-12T23:07Znever http://cmlsupport.gn.apc.org/videos/second-and-third-generation-tkis-%E2%80%93-nilotinib-dasatinib-ponatinib-bosutinib-%E2%80%93-how-should-we2019-10-11T18:05Znever http://cmlsupport.gn.apc.org/videos/chronic-myeloid-leukaemia-%E2%80%93-what-it2019-10-11T18:07Znever http://cmlsupport.gn.apc.org/videos/starting-first-line-treatment-update-imatinib2019-10-12T18:27Znever http://cmlsupport.gn.apc.org/videos/how-response-treatment-measured-and-treatment-targets-pcr-assay2019-10-12T18:29Znever http://cmlsupport.gn.apc.org/videos/questions-answers-panel2019-10-12T18:44Znever http://cmlsupport.gn.apc.org/article/investigation-use-app-technology-patients-cml2019-11-05T21:30Znever http://cmlsupport.gn.apc.org/article/do-persons-chronic-myeloid-leukaemia-have-normal-or-near-normal-survival2020-01-06T20:27Znever http://cmlsupport.gn.apc.org/article/ruxolitinib-shows-noteworthy-responses-patients-atypical-cml2020-01-14T16:46Znever http://cmlsupport.gn.apc.org/article/managing-cml-treatment-free-remission-tfr-proposal-gimema-cml-wp2020-02-29T10:36Znever http://cmlsupport.gn.apc.org/article/update-investigation-use-app-technology-patients-cml2020-02-19T17:19Znever http://cmlsupport.gn.apc.org/article/nccn-2020-quick-guide-guidelines-cml-patients2020-02-28T11:40Znever http://cmlsupport.gn.apc.org/article/european-leukemianet-2020-recommendations-treating-cml2020-03-04T15:48Znever http://cmlsupport.gn.apc.org/article/guidance-icmlf-regarding-covid-192020-03-10T15:27Znever http://cmlsupport.gn.apc.org/article/cml-and-covid-19-case-collection-icmlf2020-03-19T20:30Znever http://cmlsupport.gn.apc.org/article/public-health-england-covid-19-guidance-document2020-03-27T22:07Znever http://cmlsupport.gn.apc.org/article/recommendation-ncri-cml-subgroup-updated-27th-march-20202020-03-27T15:54Znever http://cmlsupport.gn.apc.org/article/icmlf-faq-cml-tki-treatment-and-covid-19-disease2020-04-03T13:59Znever http://cmlsupport.gn.apc.org/article/join-covid-symptom-study2020-05-23T11:29Znever http://cmlsupport.gn.apc.org/article/covid-19-persons-chronic-myeloid-leukaemia2020-06-04T13:17Znever http://cmlsupport.gn.apc.org/article/cml-management-time-covid-19-pandemic-italy2020-06-22T08:48Znever http://cmlsupport.gn.apc.org/article/late-molecular-recurrences-patients-chronic-myeloid-leukemia-experiencing-treatment-free2020-07-28T09:57Znever http://cmlsupport.gn.apc.org/article/asciminib-abl001-meets-primary-endpoint-phase-iii-acembl-study2020-08-27T10:23Znever http://cmlsupport.gn.apc.org/article/british-society-haematology-guideline-diagnosis-and-management-cml2020-08-31T16:39Znever http://cmlsupport.gn.apc.org/article/moving-2013-2020-european-leukemianet-recommendations-treating-cml-what-has-changed-over-72020-08-31T16:49Znever http://cmlsupport.gn.apc.org/article/covid-19-therapy-drug-interactions2020-10-10T14:01Znever http://cmlsupport.gn.apc.org/article/efficacy-and-safety-results-ascembl-multicenter-open-label-phase-3-study-asciminib-vs2021-01-26T15:35Znever http://cmlsupport.gn.apc.org/article/discontinuation-tyrosine-kinase-inhibitors-chronic-myeloid-leukemia-when-and-whom2021-02-04T13:02Znever http://cmlsupport.gn.apc.org/article/models-care-chronic-myeloid-leukemia-patients-during-covid%E2%80%9019-pandemic2021-05-14T09:54Znever http://cmlsupport.gn.apc.org/article/targeting-chronic-myeloid-leukemia-stemprogenitor-cells-using-venetoclax-loaded2021-05-16T14:22Znever http://cmlsupport.gn.apc.org/article/successful-tyrosine-kinase-inhibitor-discontinuation-outsideclinical-trials-%E2%80%94-data2021-06-30T10:31Znever http://cmlsupport.gn.apc.org/article/british-society-haematology-guideline-diagnosis-and-management-chronic-myeloid-leukaemia2021-06-30T10:54Znever http://cmlsupport.gn.apc.org/clinical-trials/asciminib-phase-3-asemble-trial2021-07-27T10:30Znever http://cmlsupport.gn.apc.org/article/uk-patients-needed-myeloidscan-study-%E2%80%93-long-covid-patients-myeloid-blood-cancers2022-01-31T11:29Znever http://cmlsupport.gn.apc.org/article/long-term-follow-lower-dose-dasatinib-50-mg-daily2021-09-03T13:34Znever http://cmlsupport.gn.apc.org/article/treatment-free-remission-chronic-myeloid-leukemia-can-we-identify-prognostic-factors2021-09-07T13:28Znever http://cmlsupport.gn.apc.org/article/results-acembl-trial-aciminib-vs-bosutinib2021-09-07T14:24Znever http://cmlsupport.gn.apc.org/article/vit-d-story-behind-beginning-daction2021-10-01T09:40Znever http://cmlsupport.gn.apc.org/article/icmlf-cml-knowledge-centre2021-10-07T12:37Znever http://cmlsupport.gn.apc.org/article/cml-highlights-63rd-ash-annual-meeting2021-11-24T13:22Znever http://cmlsupport.gn.apc.org/article/taming-gatekeeper-ponatinib-dose-holds-key2021-12-03T13:14Znever http://cmlsupport.gn.apc.org/article/european-leukemianet-2020-recommendations-treating-chronic-myeloid-leukemia2021-12-30T13:32Znever http://cmlsupport.gn.apc.org/article/2021%E2%80%99s-top-10-blogs-grassrootshealth2021-12-30T14:31Znever http://cmlsupport.gn.apc.org/videos/dr-michael-cohen-discusses-importance-vitamin-d-and-zinc-optimisation-immune-system2021-12-30T16:49Znever http://cmlsupport.gn.apc.org/videos/dr-john-campell-natural-immunity-excellent-covid-19-infection2022-01-25T13:43Znever http://cmlsupport.gn.apc.org/videos/immunology-professor-robert-clancy2022-01-25T14:02Znever http://cmlsupport.gn.apc.org/videos/tim-spector-omicrons-second-peak-how-high-will-it-go2022-02-06T11:56Znever http://cmlsupport.gn.apc.org/videos/are-omicron-vaccines-needed2022-02-06T15:42Znever http://cmlsupport.gn.apc.org/article/63rd-ash-annual-meeting-cmladnet-conference-report2022-02-21T15:52Znever http://cmlsupport.gn.apc.org/article/top-vitamin-d-research-papers-20212022-02-23T10:45Znever http://cmlsupport.gn.apc.org/article/discontinuation-tyrosine-kinase-inhibitors-patients-chronic-myeloid-leukemia-review2022-03-03T12:10Znever http://cmlsupport.gn.apc.org/article/tfr-chronic-myeloid-leukemia-lights-and-shadows-several-studies-nk-cell-numbers-or2022-03-26T10:21Znever http://cmlsupport.gn.apc.org/article/icmlf-newsletter-20222022-06-18T12:53Znever http://cmlsupport.gn.apc.org/article/icmlf-highlights-eha-20222022-06-28T10:15Znever http://cmlsupport.gn.apc.org/article/icmlf-conversation-treatment-cml-patients-after-failure-2-tkis2022-07-23T12:49Znever http://cmlsupport.gn.apc.org/article/icmlf-publications-selection-interesting-articles-cml-peer-reviewed-journals2023-02-28T08:07Znever http://cmlsupport.gn.apc.org/article/icmlf-forum-2022-next-big-challenges-cml-webstreams2023-03-04T15:52Znever http://cmlsupport.gn.apc.org/article/icmlf-publicaions2023-05-04T11:32Znever http://cmlsupport.gn.apc.org/article/cml-horizons-2024-videos-and-presentations2024-07-05T11:05Zyearly http://cmlsupport.gn.apc.org/article/investigation-patient-experience-and-perceptions-generic-tkis-treatment-cml2025-02-20T08:26Zyearly http://cmlsupport.gn.apc.org/understandingCML2026-02-24T21:01Zdaily http://cmlsupport.gn.apc.org/section/cause-diagnosis-and-testing2026-01-24T22:22Zmonthly http://cmlsupport.gn.apc.org/section/recently-diagnosed-options-and-outlook2026-01-22T20:56Zmonthly http://cmlsupport.gn.apc.org/section/living-cml2026-02-24T21:05Zdaily http://cmlsupport.gn.apc.org/section/changes-therapy2026-01-22T15:50Zmonthly http://cmlsupport.gn.apc.org/about/privacy-policy2021-07-23T13:46Znever http://cmlsupport.gn.apc.org/organisations/imperial-college-healthcare-nhs-trust2015-07-28T15:15Znever http://cmlsupport.gn.apc.org/clinical-trials/destiny2015-11-20T16:41Znever http://cmlsupport.gn.apc.org/clinical-trials/abl001%E2%80%8B2015-11-20T17:11Znever http://cmlsupport.gn.apc.org/section/testing-cml2022-09-15T16:48Znever http://cmlsupport.gn.apc.org/section/inside-cell2021-07-23T16:14Znever http://cmlsupport.gn.apc.org/section/about-qrt-pcr-test2015-07-28T14:13Znever http://cmlsupport.gn.apc.org/section/bcr-abl1-gene-and-its-messenger-rna-protein-tyrosine-kinase-bcr-abl12021-07-23T16:31Znever http://cmlsupport.gn.apc.org/section/how-q-pcr-testing-works-practice2021-07-23T17:01Znever http://cmlsupport.gn.apc.org/section/testing-response-treatment2015-07-28T14:12Znever http://cmlsupport.gn.apc.org/section/treating-cml2021-07-25T17:10Znever http://cmlsupport.gn.apc.org/section/patient-information2021-07-25T16:56Znever http://cmlsupport.gn.apc.org/section/side-effects-tki-therapies2021-07-23T14:34Znever http://cmlsupport.gn.apc.org/clinical-trials/enestfreedom2015-07-28T14:31Znever http://cmlsupport.gn.apc.org/clinical-trials/simplicity2015-07-28T14:31Znever http://cmlsupport.gn.apc.org/clinical-trials/enestop2015-07-28T14:34Znever http://cmlsupport.gn.apc.org/clinical-trials/euro-ski2015-09-16T18:02Znever http://cmlsupport.gn.apc.org/clinical-trials/stim-22015-07-28T14:35Znever http://cmlsupport.gn.apc.org/clinical-trials/cml1113-gimema2015-07-28T14:34Znever http://cmlsupport.gn.apc.org/clinical-trials/dasapost2015-07-28T14:34Znever http://cmlsupport.gn.apc.org/clinical-trials/enestpath2015-07-28T14:31Znever http://cmlsupport.gn.apc.org/about2021-07-23T13:32Znever http://cmlsupport.gn.apc.org/section/about-site2021-07-23T13:41Znever http://cmlsupport.gn.apc.org/section/how-you-can-support-us2015-07-28T16:30Znever http://cmlsupport.gn.apc.org/section/our-funding-policy2021-07-25T16:39Znever http://cmlsupport.gn.apc.org/section/what-cml2021-07-23T15:01Znever http://cmlsupport.gn.apc.org/section/about-philadelphia-chromosome2021-07-23T16:24Znever http://cmlsupport.gn.apc.org/section/forum-usage-agreement2021-07-23T13:37Znever http://cmlsupport.gn.apc.org/section/acknowledgments2021-07-23T13:43Znever http://cmlsupport.gn.apc.org/section/normal-blood-counts2022-03-14T12:25Znever http://cmlsupport.gn.apc.org/section/international-standardisation-test-results2015-09-21T22:12Znever http://cmlsupport.gn.apc.org/section/templates2015-09-18T11:17Znever http://cmlsupport.gn.apc.org/section/template-questions-blood-test-progress-updates2015-09-17T14:09Znever http://cmlsupport.gn.apc.org/section/10-most-important-things-remember-about-cml-testing2015-09-21T22:11Znever http://cmlsupport.gn.apc.org/section/how-ensure-you-have-optimal-response-tki-therapy2015-07-29T16:14Znever http://cmlsupport.gn.apc.org/section/future-cml-testing2015-07-28T14:12Znever http://cmlsupport.gn.apc.org/section/three-phases-cml2021-07-23T16:48Znever http://cmlsupport.gn.apc.org/section/your-diagnosis-02021-07-23T14:22Znever http://cmlsupport.gn.apc.org/section/template-questions-early-meetings-your-treatment-team2026-02-25T11:12Zhourly http://cmlsupport.gn.apc.org/content/nigel-deekes2015-09-18T01:19Znever http://cmlsupport.gn.apc.org/content/david-fitzgerald2018-02-20T12:06Znever http://cmlsupport.gn.apc.org/content/karen-adams-walker2016-08-06T15:14Znever http://cmlsupport.gn.apc.org/content/denise-clayson2015-09-18T01:20Znever http://cmlsupport.gn.apc.org/content/olivia-bell2015-09-18T01:20Znever http://cmlsupport.gn.apc.org/section/just-diagnosed2021-07-27T11:00Znever http://cmlsupport.gn.apc.org/clinical-trials/dasision2015-07-29T13:54Znever http://cmlsupport.gn.apc.org/videos/what-if-what-now-milestones-cml2016-08-02T18:11Znever http://cmlsupport.gn.apc.org/content/richard-willoughby2015-09-14T10:29Znever http://cmlsupport.gn.apc.org/section/recommended-books2015-09-18T11:16Znever http://cmlsupport.gn.apc.org/content/sandy-craine2015-09-17T14:38Znever http://cmlsupport.gn.apc.org/section/about-our-website2021-07-23T13:42Znever http://cmlsupport.gn.apc.org/section/press-and-media2021-07-23T13:50Znever http://cmlsupport.gn.apc.org/node/6242017-08-03T10:34Znever http://cmlsupport.gn.apc.org/node/7322017-06-27T13:08Znever http://cmlsupport.gn.apc.org/node/7942015-09-25T11:47Znever http://cmlsupport.gn.apc.org/node/8382015-09-25T12:17Znever http://cmlsupport.gn.apc.org/node/9542015-09-25T11:21Znever http://cmlsupport.gn.apc.org/node/9552015-09-25T11:18Znever http://cmlsupport.gn.apc.org/node/9772015-09-25T11:44Znever http://cmlsupport.gn.apc.org/article/cancer-drugs-fund-cml-support-signatory-letter-times-november-4th-day-bosutinib-delisted2015-12-22T14:46Znever http://cmlsupport.gn.apc.org/event/uk-patients-and-carers-day-20152016-04-05T11:37Znever http://cmlsupport.gn.apc.org/section/templates-send-your-mp2015-09-25T16:13Znever